We will see this technology pending FDA clearance available to tetraplegic patients as early as mid of next year, so 2023. The risk of an implant, which obviously we address by working with the FDA and getting clearance and making sure that the product is safe,. Will that be good enough for a consumer to just put in so that they can do a P2P communication? No. But we're working on it.
The Sunday Times’ tech correspondent Danny Fortson brings on Marcus Gerhardt, chief executive of Blackrock Neurotech, to talk about his boarding school days in Wales (4:00), his dotcom adventures (10:00), pivoting to brain-computer interfaces (16:00), the “Utah array” (18:40), how in 2006 the first person sent an email with his thoughts (20:30), starting the company (23:00), the state of the technology today (26:40), targeting tetraplegics (33:00), getting investment (38:15), going to market (41:30), and reaching an inflection point (47:40).
Hosted on Acast. See acast.com/privacy for more information.